A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. - Wikidata - awgldk - TriplyDB

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

http://www.wikidata.org/entity/Q46177222

about

Non-alcoholic fatty liver disease: what the clinician needs to know.NAFLD and Chronic Kidney Disease Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment Biomarkers in nonalcoholic fatty liver disease Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.Novel algorithm for non-invasive assessment of fibrosis in NAFLD Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers Liver fibrosis markers of nonalcoholic steatohepatitis.Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.Nonalcoholic fatty liver disease: Diagnostic biomarkers.Cell death biomarker M65 is a useful indicator of liver inflammation and fibrosis in chronic hepatitis B: A cross-sectional study of diagnostic accuracy Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis.Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX.Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion.Tissue Inhibitor Of Matrix Metalloproteinase-1 Is Required for High-Fat Diet-Induced Glucose Intolerance and Hepatic Steatosis in Mice Cardiometabolic aspects of the polycystic ovary syndrome.Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants The Wide and Complex Field of NAFLD Biomarker Research: Trends.Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load.Genetic and clinical markers of elevated liver fat content in overweight and obese Hispanic children.How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives.Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?Liver tissue metabolic profiling and pathways of non-alcoholic steatohepatitis in rats.The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes.Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study.

P2860

Q24563068-D85CDE8C-1715-474D-9051-31D222224AA8 Q26752759-0899D251-2E2D-4E8A-B130-98273F9EC4FC Q26800894-43C09246-34E4-400D-8CA3-F8C4CB28A65C Q28080136-247D66AD-C5CB-482B-9C42-C58070980005 Q28080541-479841DC-AE46-41BD-B3A7-ACB71DE176C2 Q28082686-3DDC1A2B-3AFB-4FA1-80C4-A3EBB84BE30A Q28289982-E5DD410D-EA51-4CEB-A029-5AD0AAC82760 Q28542723-2F5DC364-A7CC-4736-8F4B-7959F09762E7 Q30407625-D169FF68-0584-46EB-824C-43F39A9FABA8 Q30432576-3F9C736A-69F3-4A4C-97D2-A38DCC569951 Q30994991-767E57BA-AC0C-4046-86DB-C8B58E73CD87 Q33706254-8C3E4C5C-3FE8-4B83-BEBD-F3117FE1AFE8 Q33714356-1E4A12E6-C4A5-4EDB-8E37-1DFBC9A8050F Q34256132-27000C62-C907-43B7-B784-EBF165CF4BEC Q34802423-CE528CF1-6478-4819-A0E0-6290363CB28B Q34819164-F95DA870-6CFD-4232-96B3-CE7F24922A70 Q35126638-C6EDDDE0-D9CA-4BB0-808A-0E849590F4C2 Q35689623-E89A1A4E-BA64-47AE-92FF-486EF37DC250 Q36287892-BDE19EF5-D83C-4747-AB26-3B6A3D4E665B Q36566846-A337093A-0187-470B-971C-C2A557086C22 Q36782785-72221122-8CAD-40E6-8A56-7C1DDB8E40EA Q36962085-C99145FD-E47C-4077-BC66-24D32B6E209B Q36982020-2F3DB257-7601-4FBA-B8FB-38172781BED9 Q37206503-5CA62B83-4B54-4057-A36B-B354F871DE50 Q37373386-AEEB76CF-1B36-4D53-BCE0-5C0D43385B1F Q37401637-2EAB1DED-4811-4584-B107-DC0366F5CB61 Q37613375-8B6A25F8-110B-4379-9891-9B16055EDD80 Q37689828-FD593778-3121-4FC3-843B-DEC912AD54E1 Q37811071-BB8A7A38-2175-4831-AB70-9F6E566DADED Q38128548-58D1594B-FA87-4604-BCE5-9EA0C78DC401 Q38204970-AA2DC875-C397-4262-87F6-B0F4DCEBBF65 Q38494198-22656F26-404A-47B5-AA57-1C017CA23A3C Q38549856-F364113D-D00D-4D5F-B6B4-F607A1CFBA81 Q38720197-A4EDE48D-51B2-48E3-81BF-44ABF09EDD11 Q38772737-65EF4898-C98A-4A1E-A53C-298C1DEF4902 Q38948643-E3BAE022-036B-4125-BE06-5FEA653D22E9 Q40294716-47877B7A-F346-40A0-8532-0CD35607FADA Q42284206-F25B9492-4F44-40C3-8CBB-721443FF4D56 Q44697151-001B485F-740E-40A1-BE4D-63486FA52C04 Q44790460-7B1FE792-DD22-4152-B52B-260373F2641C

P2860

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

http://www.wikidata.org/entity/Q46177222

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

@en

A biomarker panel for non-alcoholic steatohepatitis

@nl

type

label

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

@en

A biomarker panel for non-alcoholic steatohepatitis

@nl

prefLabel

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

@en

A biomarker panel for non-alcoholic steatohepatitis

@nl

P1433

Q46177222-619B4AB1-5F6D-4342-B998-AD7447DC7EF5

P1476

Q46177222-94352EDC-C855-4351-8836-90E19FDDFD49

P2093

Q46177222-399BADE6-479F-4420-8850-8154E4BD26FA

Q46177222-52798B1B-B5C1-4D87-819C-D80628F9A97D

Q46177222-62A13308-5A9C-47AA-BE47-A98CFFD7EA26

Q46177222-77219234-96CB-4653-B408-CFD1C2D5AF48

Q46177222-79AD19C0-D934-4BBC-95BC-EEBC6912B82F

Q46177222-83834162-1974-45CC-9A79-049A04DFFA67

Q46177222-90096CCD-8125-4883-8601-A0C337C21A95

Q46177222-A5F00734-C1B2-473D-9925-1A94921D97AB

Q46177222-C4B7E465-7407-4722-815B-5547A3676AF8

Q46177222-D772E107-3E39-4C29-8B56-EDD3EA57B430

P2860

Q46177222-052C5437-CF75-4416-AE1B-99627519E2FC

Q46177222-0633F754-BBF5-4116-82A2-47A14A6A99D3

Q46177222-08617B09-187F-407A-9ADF-4FB705D8A8F3

Q46177222-08845143-6A6D-49BC-B3D2-280D29C953DC

Q46177222-17650BDB-389A-4E28-B7FD-4FEB7676A85B

Q46177222-1AA79EE1-697D-423C-9D17-6EE0BF1E2153

Q46177222-208F0D0C-9F8B-48EF-AC0D-473336EBD20B

Q46177222-3976C7A8-C3D0-484A-9BBD-A68A2628A610

Q46177222-43AB500F-E34E-4E87-BC6B-B5084D9B8204

Q46177222-526356EC-1938-4B8F-8AE2-F1AD66D46207

P2888

Q46177222-E66D091A-DD74-45B9-8FEE-834BD8439C16

P304

Q46177222-F37B4E75-9EF5-4840-9801-9C3CA0C943E6

P31

Q46177222-553A04CC-8F43-4210-9194-10EF35A8DBDA

P356

Q46177222-D347453D-B073-4B96-BBAE-9AEE0DFE19F2

P433

Q46177222-A91BE60F-80FB-4FE6-A174-37F1D3B24347

P478

Q46177222-39A39788-0A8F-460D-A3FA-0D571232D759

P577

Q46177222-9D787D22-895C-4A73-B090-ADD0BF362A3D

P5875

Q46177222-925089D9-7FD4-478A-8C49-68FDB0B0ADB5

P698

Q46177222-B24D7419-0671-4C70-A79A-07C2787C7516

P921

Q46177222-187995FA-E193-4EF5-96FC-16AE4E23A067

Q46177222-54028AC9-5EFA-493E-B55C-B8A74B0D5BE9

P356

S11695-010-0204-1

P1433

Obesity Surgery

P1476

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

@en

P2093

Ancha Baranova

http://www.w3.org/2001/XMLSchema#string

Arian Afendy

http://www.w3.org/2001/XMLSchema#string

Aybike Birerdinc

http://www.w3.org/2001/XMLSchema#string

Maria Stepanova

http://www.w3.org/2001/XMLSchema#string

Nila Rafiq

http://www.w3.org/2001/XMLSchema#string

Noreen Hossain

http://www.w3.org/2001/XMLSchema#string

Sandra Page

http://www.w3.org/2001/XMLSchema#string

Zachary Goodman

http://www.w3.org/2001/XMLSchema#string

Zahra Younoszai

http://www.w3.org/2001/XMLSchema#string

Zobair M Younossi

http://www.w3.org/2001/XMLSchema#string

P2860

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Long-term follow-up of patients with NAFLD and elevated liver enzymes

Pathogenesis of non-alcoholic steatohepatitis: human data.

A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis.

Etiopathogenesis of nonalcoholic steatohepatitis.

Nonalcoholic fatty liver disease: an agenda for clinical research.

Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection.

Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan).

Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

P2888

s11695-010-0204-1

P304

431-439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11695-010-0204-1

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44658502

http://www.w3.org/2001/XMLSchema#string

P698

20532833

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis